Scottish HTA OKs Neratinib For Early-Stage Breast Cancer
Treatment Fills An Unmet Need, Say Clinical Experts
Executive Summary
A product that was initially turned down for marketing approval in the EU has now been given the green light for use on the National Health Service in Scotland, following a similar recommendation in England late last year.